ADC Therapeutics

• NCT05991388

  Collaborator, Phase 2/3, Recruiting, 210 people, 14 Aug 2023

• NCT05600686

  Collaborator, Phase 2, Active, not recruiting, 24 people, 31 Oct 2022

• NCT05228249

  Collaborator, Phase 1, Withdrawn, 0 people, 8 Feb 2022

• NCT05190705

  Collaborator, Phase 2, Active, not recruiting, 21 people, 13 Jan 2022

• NCT04974996

  Phase 1, Withdrawn, 0 people, 23 Jul 2021

• NCT04384484

  Phase 3, Active, not recruiting, 440 people, 12 May 2020

• NCT03684694

  Phase 1/2, Terminated, 136 people, 26 Sept 2018

• Global, regional, and national prevalence of second-hand smoke and attributable disease burden in 204 countries and territories, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023

  Consulting or advice, Fees or honoraria, Grants or research support, 7 Sept 2026

Sources: pubmed.ncbi.nlm.nih.gov